 CTI BioPharma Corp NASDAQ: CTIC has completed a rolling marketing application submission to the FDA seeking approval of pacritinib for myelofibrosis patients with severe thrombocytopenia platelet counts less than 50 x 109L. CTIC had previously announced the results of a pre-NDA meeting wherein an agreement was reached on the submission package to be based upon available data from the completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 trials. 